Literature DB >> 21421593

Serum urea concentration is probably not related to outcome in ICU patients with AKI and renal replacement therapy.

Wouter De Corte1, Raymond Vanholder, Annemieke W Dhondt, Jan J De Waele, Johan Decruyenaere, Christian Danneels, Stefaan Claus, Eric A J Hoste.   

Abstract

BACKGROUND: Acute kidney injury (AKI) is a common complication in patients admitted to the intensive care unit (ICU). Among other variables, serum urea concentrations are recommended for timing of initiation of renal replacement therapy (RRT). The aim of this study was to evaluate whether serum urea concentration or different serum urea concentration cutoffs as recommended in the literature were associated with in-hospital mortality at time of initiation of RRT for AKI.
METHODS: This is a retrospective single- centre study during a 3-year period (2004-07), in a 44-bed tertiary care centre ICU of adult AKI patients who were treated with RRT.
RESULTS: Three hundred and two patients were included: 68.9% male, median age 65 years and an APACHE II score of 21. The overall in-hospital mortality was 57.9%. Non-survivors were older (67 versus 64 years, P = 0.016) and had a higher APACHE II score (22 versus 20, P < 0.001). At time of initiation of RRT, they were more severely ill and had a lower serum urea concentration compared to survivors (130 versus 141 mg/dL, P = 0.038). Serum urea concentration, as well as the different historical serum urea concentration cut-offs had low area under the curves for the receiver operating characteristic curve for prediction of mortality. In multivariate analysis, age, and at time of initiation of RRT, potassium, SOFA score with exclusion of points for AKI and RIFLE class were associated with mortality, but serum urea concentration and the different cut-offs were not.
CONCLUSIONS: This retrospective study suggests that serum urea concentration and serum urea concentration cut-offs at time of initiation of RRT have no predictive value for in-hospital mortality in ICU patients with AKI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421593     DOI: 10.1093/ndt/gfq840

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Dialysis versus nondialysis in patients with AKI: a propensity-matched cohort study.

Authors:  F Perry Wilson; Wei Yang; Carlos A Machado; Laura H Mariani; Yuliya Borovskiy; Jeffrey S Berns; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 8.237

2.  A policy of preemption: the timing of renal replacement therapy in AKI.

Authors:  F Perry Wilson
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-08       Impact factor: 8.237

3.  A Novel Predictive Model for Hospital Survival in Patients who are Critically Ill with Dialysis-Dependent AKI: A Retrospective Single-Center Exploratory Study.

Authors:  Anirban Ganguli; Saad Farooq; Neerja Desai; Shreedhar Adhikari; Vatsal Shah; Michael J Sherman; Judith H Veis; Jack Moore
Journal:  Kidney360       Date:  2022-01-25

4.  Population-based incidence, mortality and quality of life in critically ill patients treated with renal replacement therapy: a nationwide retrospective cohort study in Finnish intensive care units.

Authors:  Suvi T Vaara; Ville Pettilä; Matti Reinikainen; Kirsi-Maija Kaukonen
Journal:  Crit Care       Date:  2012-01-20       Impact factor: 9.097

5.  Continuous Renal Replacement Therapy for Acute Renal Failure in Patients with Traumatic Brain Injury.

Authors:  Chang-Yong Park; Hyun-Yong Choi; Nam-Kyu You; Tae Hoon Roh; Sook Jin Seo; Se-Hyuk Kim
Journal:  Korean J Neurotrauma       Date:  2016-10-31

Review 6.  Sex differences in acute kidney injury requiring dialysis.

Authors:  Joel Neugarten; Ladan Golestaneh; Nitin V Kolhe
Journal:  BMC Nephrol       Date:  2018-06-08       Impact factor: 2.388

7.  An isolated elevation in blood urea level is not 'uraemia' and not an indication for renal replacement therapy in the ICU.

Authors:  Jack Mackenzie; Bobby Chacko
Journal:  Crit Care       Date:  2017-11-13       Impact factor: 9.097

8.  A Micellar Formulation of Quercetin Prevents Cisplatin Nephrotoxicity.

Authors:  Alfredo G Casanova; Marta Prieto; Clara I Colino; Carmen Gutiérrez-Millán; Barbara Ruszkowska-Ciastek; Esther de Paz; Ángel Martín; Ana I Morales; Francisco J López-Hernández
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

9.  Protective Effect of Quercetin 3-O-Glucuronide against Cisplatin Cytotoxicity in Renal Tubular Cells.

Authors:  Daniel Muñoz-Reyes; Alfredo G Casanova; Ana María González-Paramás; Ángel Martín; Celestino Santos-Buelga; Ana I Morales; Francisco J López-Hernández; Marta Prieto
Journal:  Molecules       Date:  2022-02-15       Impact factor: 4.411

10.  Clinical Characteristics and 30-Day Outcomes of Intermittent Hemodialysis for Acute Kidney Injury in an African Intensive Care Unit.

Authors:  Arthur Kwizera; Janat Tumukunde; Lameck Ssemogerere; Emmanuel Ayebale; Peter Agaba; Jamali Yakubu; Aggrey Lubikire; Mary Nabukenya; Robert Kalyesubula
Journal:  Biomed Res Int       Date:  2016-03-03       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.